Effects of PCSK9 inhibition on glucose metabolism and β-cell function in humans: a pilot study
BackgroundAnti-PCSK9 monoclonal antibodies are effective in reducing LDL-C and cardiovascular events by neutralizing circulating PCSK9. PCSK9, however, is also expressed in tissues, including the pancreas, and studies on PCSK9 KO mice have shown impaired insulin secretion. Statin treatment is alread...
Main Authors: | Simona Moffa, Teresa Mezza, Pietro Manuel Ferraro, Gianfranco Di Giuseppe, Chiara M. A. Cefalo, Francesca Cinti, Flavia Impronta, Umberto Capece, Gea Ciccarelli, Andrea Mari, Alfredo Pontecorvi, Andrea Giaccari |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1124116/full |
Similar Items
-
Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01) -
Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
by: Konstantinos Koskinas, et al.
Published: (2016-07-01) -
Sex and statin-related genetic associations at the PCSK9 gene locus: results of genome-wide association meta-analysis
by: Janne Pott, et al.
Published: (2024-03-01) -
Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
by: Christopher LaFratte, et al.
Published: (2023-09-01) -
Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management
by: Mohd Waiz, et al.
Published: (2022-01-01)